Skip to main content
OpenTrials

Clinical trial condition

Fabry Disease

Explore clinical trials studying Fabry Disease. Study availability and eligibility vary by location and protocol.

175 public trials 38 recruiting studies
Refine in advanced search Browse all conditions

Fabry Disease trial results

Completed

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

NCT03180840

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • UAB Medicine Birmingham, Alabama, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Infusion Associates Grand Rapids, Michigan, United States
View all 14 locations
View Trial Details
Completed

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

NCT01678898

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics Sacramento, California, United States
  • Department of Human Genetics, Emory University School of Medicine Atlanta, Georgia, United States
  • University of Iowa Health Clinics Iowa City, Iowa, United States
  • University of Kansas Medical Center Kansas City, Kansas, United States
View all 14 locations
View Trial Details
Completed

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

NCT03018730

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • Royal Melbourne Hospital Parkville, Victoria, Australia
  • Capital Health Halifax, Nova Scotia, Canada
  • Vseobecna fakultni nemocnice v Praze Prague, Czechia
  • Academisch Medisch Centrum Amsterdam, Netherlands
View Trial Details
Completed

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +29 more
Locations
  • UAB Medicine Birmingham, Alabama, United States
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • University of California Irvine Center Orange, California, United States
  • University of California San Diego San Diego, California, United States
View all 29 locations
View Trial Details
Completed

Extension Study of PRX-102 for up to 60 Months

NCT01981720

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • University of Florida Gainesville, Florida, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Johns Hopkins University School of Medicine Baltimore, Maryland, United States
  • Institute of Metabolic Disease Dallas, Texas, United States
View Trial Details
Completed

Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion

NCT05186324

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • #02 Birmingham, Alabama, United States
  • #03 Atlanta, Georgia, United States
  • #04 Iowa City, Iowa, United States
  • #11 Grand Rapids, Michigan, United States
View Trial Details
Completed

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • Clinical Study Site Tampa, Florida, United States
  • Clinical Study Site Atlanta, Georgia, United States
  • Clinical Study Site Minneapolis, Minnesota, United States
  • Clinical Study Site Columbia, Missouri, United States
View Trial Details

Related conditions